Local News

• Myozyme produced at the 2000 L bioreactor scale to receive accelerated approval  Genzyme announced that the FDA plans an Accelerated Approval for Myozyme(R) (alglucosidase alfa) produced at the 2000 L bioreactor scale for the treatment of Late Onset Pompe disease.
  Genzyme Corporation November 17, 2008  
• Lilly licenses U.S. rights for tadalafil PAH indication to United Therapeutics  Eli Lilly and Company and United Therapeutics announced that the two companies have entered into a license and a supply agreement related to the U.S. commercialization rights for the pulmonary arterial hypertension (PAH) indication of Lilly's molecule, tadalafil.
  United Therapeutics Corporation November 17, 2008  
• Pfizer launches global regenerative medicine research unit  Pfizer announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells.
  Pfizer Inc. November 14, 2008  
• Iowa Biotechnology Association Receives 2008 Best of Des Moines Award  The Iowa Biotechnology Association has been selected for the 2008 Best of Des Moines Award in the Associations category by the U.S. Local Business Association (USLBA). The USLBA "Best of Local Business" Award Program recognizes outstanding local businesses throughout the country.
  U.S. Local Business Association November 14, 2008  
• New antibiotic against serious infections - receives first approval in Europe  Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA(TM) (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.
  Johnson & Johnson November 13, 2008  
• FDA approves low-dose regimen of PREMARIN vaginal cream  PREMARIN(R) Vaginal Cream 0.5 g has been approved by the U.S. Food and Drug Administration (FDA) for a new indication and a new less frequent twice-weekly dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals.
  Wyeth November 13, 2008  
• Taking science personally  A few years after Michael J. Fox revealed that he had Parkinson's disease, he attended the annual charity auction for the Robin Hood Foundation, a New York philanthropy financed largely from donations by wealthy hedge fund managers. Mr. Fox was in his late 30s at the time.
  The New York Times November 13, 2008  Joe Nocera
• GARDASIL(R) demonstrated efficacy in preventing HPV-related disease in males in Phase III  GARDASIL(R), the cervical cancer vaccine from Merck, prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.
  Merck & Co., Inc. November 13, 2008  
• NeoPharm announces third quarter 2008 financial results  NeoPharm announced its third quarter 2008 financial results. For the third quarter ended September 30, 2008, NeoPharm reported a net loss of $2.4 million, or ($0.08) per basic and diluted share, as compared to a net loss of $881,000, or ($0.03) per share, for the same period last year.
  NeoPharm, Inc. November 12, 2008  
• SEROQUEL XR and SEROQUEL approved in Europe for new indications for bipolar disorder  AstraZeneca announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder.
  AstraZeneca November 12, 2008  

   (next 10 articles)